The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2021 Virtual KU Hematology and Medical Oncology Review
S

2021 Developments in RCC & UC: Pembro for ccRCC, Sacituzumab Govitecan for mUC, Enfortumab Vedotin for Advanced UC, Bladder Sparing Treatment

By 2021 Virtual KU Hematology and Medical Oncology Review FEATURING Saqib Abbasi
By 2021 Virtual KU Hematology and Medical Oncology Review FEATURING Saqib Abbasi
0 views
July 22, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon
2021 Virtual KU Hematology and Medical Oncology Review
43:11
2021 Virtual KU Hematology and Medical Oncology Review

2021 Advances in Metastatic Sarcoma: GIST & Ripretinib, Synovial…

Feat. B. Van Tine
25:06
2021 Virtual KU Hematology and Medical Oncology Review

ASCO 2021 Survivorship Highlights: Remote Symptom Monitoring, Inpati…

Feat. E. Wulff-Burchfield
30:04
2021 Virtual KU Hematology and Medical Oncology Review

2021 Updates in HNSCC: Expert Overview of Recent Clinical Trials

Feat. B. Burtness
09:13
2021 Virtual KU Hematology and Medical Oncology Review

ASCO 2021 Updates in Head and Neck Cancers: Advanced NPC, HPV-Relate…

Feat. B. Burtness
18:15
2021 Virtual KU Hematology and Medical Oncology Review

KUMC Highlights on mCRC: Recent Data on Changes in the SoC

Feat. W. Sun
06:25
2021 Virtual KU Hematology and Medical Oncology Review

2021 KUMC Metastatic Prostate Cancer Updates: 177Lu-PSMA-617 in mCRP…

Feat. S. Abbasi
08:08
2021 Virtual KU Hematology and Medical Oncology Review

2021 Developments in RCC & UC: Pembro for ccRCC, Sacituzumab Gov…

Feat. S. Abbasi
15:17
2021 Virtual KU Hematology and Medical Oncology Review

2021 Advances in CML: Prognostic Scores, Treatment Goals, 1L & B…

Feat. A. Yacoub
05:01
2021 Virtual KU Hematology and Medical Oncology Review

2021 Advances in Myelofibrosis: Parsaclisib + Ruxolitinib Combinatio…

Feat. A. Yacoub
10:52
2021 Virtual KU Hematology and Medical Oncology Review

2021 KUMC NDMM Updates: Assessing Current Trials for Treatment, Indu…

Feat. A. Abdallah
07:17
2021 Virtual KU Hematology and Medical Oncology Review

2021 KUMC Updates on Triple R/R MM: Does Ide-Cel Improve Overall Res…

Feat. A. Abdallah
27:42
2021 Virtual KU Hematology and Medical Oncology Review

CAR T-Cell and CRISPR in Hematologic Malignancies: Continuing Revolu…

Feat. J. McGuirk
10:44
2021 Virtual KU Hematology and Medical Oncology Review

ASCO 2021 Highlights on TNBC: Durvalumab + Neoadjuvant Therapy in Ea…

Feat. Q. Khan
08:59
2021 Virtual KU Hematology and Medical Oncology Review

ASCO 2021 Review of the OlympiA Trial for High-Risk EBC: Do Adjuvant…

Feat. Q. Khan
10:17
2021 Virtual KU Hematology and Medical Oncology Review

ASCO 2021 Updates on De-Escalation Strategies in BC: Talazoparib for…

Feat. Q. Khan